Skip to main content
SpringerLink
Log in

New and unexpected safety signals for osimertinib

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Yin Y, et al. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib Scientific Reports : 5 Dec 2022. Available from: URL: https://doi.org/10.1038/s41598-022-23834-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

New and unexpected safety signals for osimertinib. Reactions Weekly 1936, 10 (2022). https://doi.org/10.1007/s40278-022-29207-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-29207-4

Search

Navigation